Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Saved in:
| Published in | Antimicrobial Agents and Chemotherapy Vol. 56; no. 4; pp. 1985 - 1989 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.04.2012
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography tandem mass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC 50 ) for wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS (77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2 to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho = 0.61; P < 0.0001) and with postdose sampling interval (rho = −0.29; P = 0.0019). APV concentrations in CSF exceeded the median IC 50 for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens. Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography tandem mass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC50) for wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS (77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2 to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho = 0.61; P < 0.0001) and with postdose sampling interval (rho = −0.29; P = 0.0019). APV concentrations in CSF exceeded the median IC50 for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens. Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography tandem mass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC₅₀) for wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS (77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2 to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho = 0.61; P < 0.0001) and with postdose sampling interval (rho = -0.29; P = 0.0019). APV concentrations in CSF exceeded the median IC₅₀ for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens. Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography tandem mass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC₅₀) for wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS (77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2 to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho = 0.61; P < 0.0001) and with postdose sampling interval (rho = -0.29; P = 0.0019). APV concentrations in CSF exceeded the median IC₅₀ for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens.Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography tandem mass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC₅₀) for wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS (77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2 to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho = 0.61; P < 0.0001) and with postdose sampling interval (rho = -0.29; P = 0.0019). APV concentrations in CSF exceeded the median IC₅₀ for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens. |
| Author | Scott Letendre Edmund Capparelli David M. Simpson Igor Grant Benjamin B. Gelman Lauren Way Christina M. Marra J. Allen McCutchan David B. Clifford Steven S. Rossi Susan Morgello for the CHARTER Group Brookie M. Best Ronald J. Ellis Ann C. Collier David Croteau Justin McArthur |
| Author_xml | – sequence: 1 givenname: David surname: Croteau fullname: Croteau, David organization: Departments of Neurosciences, University of California, San Diego, San Diego, California, USA – sequence: 2 givenname: Scott surname: Letendre fullname: Letendre, Scott organization: Medicine, University of California, San Diego, San Diego, California, USA – sequence: 3 givenname: Brookie M. surname: Best fullname: Best, Brookie M. organization: Pediatrics, University of California, San Diego, San Diego, California, USA, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, California, USA – sequence: 4 givenname: Steven S. surname: Rossi fullname: Rossi, Steven S. organization: Pediatrics, University of California, San Diego, San Diego, California, USA – sequence: 5 givenname: Ronald J. surname: Ellis fullname: Ellis, Ronald J. organization: Departments of Neurosciences, University of California, San Diego, San Diego, California, USA – sequence: 6 givenname: David B. surname: Clifford fullname: Clifford, David B. organization: Washington University, St. Louis, Missouri, USA – sequence: 7 givenname: Ann C. surname: Collier fullname: Collier, Ann C. organization: University of Washington, Seattle, Washington, USA – sequence: 8 givenname: Benjamin B. surname: Gelman fullname: Gelman, Benjamin B. organization: University of Texas Medical Branch, Galveston, Texas, USA – sequence: 9 givenname: Christina M. surname: Marra fullname: Marra, Christina M. organization: University of Washington, Seattle, Washington, USA – sequence: 10 givenname: Justin surname: McArthur fullname: McArthur, Justin organization: Johns Hopkins University, Baltimore, Maryland, USA – sequence: 11 givenname: J. Allen surname: McCutchan fullname: McCutchan, J. Allen organization: Medicine, University of California, San Diego, San Diego, California, USA – sequence: 12 givenname: Susan surname: Morgello fullname: Morgello, Susan organization: Mount Sinai School of Medicine, New York, New York, USA – sequence: 13 givenname: David M. surname: Simpson fullname: Simpson, David M. organization: Mount Sinai School of Medicine, New York, New York, USA – sequence: 14 givenname: Lauren surname: Way fullname: Way, Lauren organization: Psychiatry, University of California, San Diego, San Diego, California, USA – sequence: 15 givenname: Edmund surname: Capparelli fullname: Capparelli, Edmund organization: Pediatrics, University of California, San Diego, San Diego, California, USA – sequence: 16 givenname: Igor surname: Grant fullname: Grant, Igor organization: Psychiatry, University of California, San Diego, San Diego, California, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25696769$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22290964$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kdFr1TAUxoNsuLvpm89SHwSFdSZpkyYgg0txUxj4Mp_Dae7pbkab1qSd-N8vd73OKewpOeR3zvm-L8fkwA8eCXnD6BljXH1ar-szKqhWOWMvyIrtblJoeUBWlEqZl4qWR-Q4xluaaqHpS3LEOddUy3JFPl9vMcCI8-Rstu7HgB7uXMjqwVv0U4DJDT5mzmc1BmzCEEfnocsuutltXpHDFrqIr_fnCflx8eW6_ppffb_8Vq-vciircsobiRuJ3DYVYyVoLVSD1grgJYJiWkglrJSqsoBYIVOaN620bdkIXTSi1cUJOV_mjnPT42YR1pkxuB7CbzOAM_--eLc1N8OdKQqmCsXSgA_7AWH4OWOcTO-ixa4Dj8McDaNUC15UhUzoxwWF2HNzO8wh2d0RZpe2SWmbh7RTmdi3T3U9CvoTbwLe7wGIFro2gLcu_uWE1LKSO4OnC2dTwDFg-4g8s5f_h1s3PfxUcu-655reLU1bd7P95QKa5NAAWCOkKQ3TShT3fKmzXw |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1002_btm2_10096 crossref_primary_10_1002_rmv_1793 crossref_primary_10_1093_jac_dks441 crossref_primary_10_1128_AAC_00486_13 crossref_primary_10_1021_mp300712a crossref_primary_10_1007_s40263_012_0018_x crossref_primary_10_1016_j_addr_2016_05_001 crossref_primary_10_1093_cid_ciu477 crossref_primary_10_1007_s40265_013_0059_6 crossref_primary_10_4155_bio_12_319 |
| Cites_doi | 10.1001/archneur.59.6.923 10.1086/523002 10.1097/QAI.0b013e3181af83d6 10.1097/QAD.0b013e328317a702 10.1128/AAC.48.2.437-443.2004 10.1212/01.WNL.0000145763.68284.15 10.1212/WNL.0b013e3181ab2b3b 10.1002/ana.410420503 10.1128/AAC.44.8.2173-2175.2000 10.1002/ana.410420504 10.1097/QAD.0b013e32832c4152 10.1007/s11095-005-5271-y 10.1007/s13365-010-0006-1 10.1073/pnas.83.18.7089 10.1002/ana.20198 10.1212/WNL.54.4.927 10.1001/archneurol.2007.31 10.1097/01.aids.0000171409.38490.48 10.1016/j.antiviral.2008.12.013 10.1016/j.tips.2009.10.001 10.1111/j.1468-1293.2010.00898.x 10.1002/ana.410420618 10.1128/AAC.45.12.3663-3668.2001 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS Copyright © 2012, American Society for Microbiology. All Rights Reserved. Copyright © 2012, American Society for Microbiology. All Rights Reserved. 2012 American Society for Microbiology |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright © 2012, American Society for Microbiology. All Rights Reserved. – notice: Copyright © 2012, American Society for Microbiology. All Rights Reserved. 2012 American Society for Microbiology |
| CorporateAuthor | for the CHARTER Group CHARTER Group |
| CorporateAuthor_xml | – name: for the CHARTER Group – name: CHARTER Group |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1128/AAC.05098-11 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 1989 |
| ExternalDocumentID | PMC3318381 05098-11 22290964 25696769 10_1128_AAC_05098_11 aac_56_4_1985 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCRR NIH HHS grantid: UL1 RR029887 – fundername: PHS HHS grantid: HHSN271201000027C – fundername: NIMH NIH HHS grantid: HHSN271201000030C – fundername: NIMH NIH HHS grantid: N01 MH022005 – fundername: PHS HHS grantid: HHSN271201000030C – fundername: NIMH NIH HHS grantid: U01 MH083545 – fundername: NIMH NIH HHS grantid: HHSN271201000027C |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM - 0R 55 AAPBV ABFLS ADACO BXI HZ RHF ZA5 7X8 5PM |
| ID | FETCH-LOGICAL-a474t-b6ed6e2cb7114a9958becc5a24ea8195685c6687caee7e1892bf6cf4b593b5f93 |
| ISSN | 0066-4804 1098-6596 |
| IngestDate | Thu Aug 21 13:27:35 EDT 2025 Fri Jul 11 11:13:14 EDT 2025 Tue Dec 28 13:59:03 EST 2021 Mon Jul 21 05:56:11 EDT 2025 Mon Jul 21 09:18:03 EDT 2025 Thu Apr 24 23:05:23 EDT 2025 Tue Jul 01 02:00:51 EDT 2025 Wed May 18 15:26:51 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Peptidases Antiretroviral agent Treatment Enzyme Enzyme inhibitor Non peptide compound Hydrolases Antiviral Concentration Cerebrospinal fluid Amprenavir Protease inhibitor |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a474t-b6ed6e2cb7114a9958becc5a24ea8195685c6687caee7e1892bf6cf4b593b5f93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://aac.asm.org/content/aac/56/4/1985.full.pdf |
| PMID | 22290964 |
| PQID | 1009523736 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | crossref_primary_10_1128_AAC_05098_11 pascalfrancis_primary_25696769 pubmed_primary_22290964 highwire_asm_aac_56_4_1985 proquest_miscellaneous_1009523736 crossref_citationtrail_10_1128_AAC_05098_11 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3318381 asm2_journals_10_1128_AAC_05098_11 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-04-01 |
| PublicationDateYYYYMMDD | 2012-04-01 |
| PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2012 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_9_2 Sevigny JJ (e_1_3_2_21_2) 2004; 63 Tozzi V (e_1_3_2_22_2) 2009; 52 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 Marra CM (e_1_3_2_15_2) 2009; 23 e_1_3_2_19_2 Saumoy M (e_1_3_2_20_2) 2011; 12 Letendre SL (e_1_3_2_13_2) 2004; 56 e_1_3_2_10_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 Varatharajan L (e_1_3_2_23_2) 2009; 82 e_1_3_2_3_2 e_1_3_2_24_2 Bachmeier CJ (e_1_3_2_2_2) 2005; 22 Cysique LA (e_1_3_2_5_2) 2009; 73 Masliah E (e_1_3_2_16_2) 1997; 42 Ellis RJ (e_1_3_2_8_2) 2002; 59 Letendre SL (e_1_3_2_14_2) 2007; 54 15349869 - Ann Neurol. 2004 Sep;56(3):416-23 19050389 - AIDS. 2009 Jan 2;23(1):83-7 11709366 - Antimicrob Agents Chemother. 2001 Dec;45(12):3663-8 10898694 - Antimicrob Agents Chemother. 2000 Aug;44(8):2173-5 15905676 - AIDS. 2005 Jun 10;19(9):949-52 3018755 - Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089-93 9392566 - Ann Neurol. 1997 Nov;42(5):679-88 12056927 - Arch Neurol. 2002 Jun;59(6):923-8 20004485 - Trends Pharmacol Sci. 2010 Jan;31(1):22-35 9403489 - Ann Neurol. 1997 Dec;42(6):963-72 14742192 - Antimicrob Agents Chemother. 2004 Feb;48(2):437-43 19731418 - J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63 21729229 - HIV Med. 2011 Aug;12(7):438-41 9392567 - Ann Neurol. 1997 Nov;42(5):689-98 15596754 - Neurology. 2004 Dec 14;63(11):2084-90 19474412 - Neurology. 2009 Aug 4;73(5):342-8 10690988 - Neurology. 2000 Feb 22;54(4):927-36 18195140 - Arch Neurol. 2008 Jan;65(1):65-70 19424052 - AIDS. 2009 Jul 17;23(11):1359-66 21174240 - J Neurovirol. 2011 Feb;17(1):3-16 16078135 - Pharm Res. 2005 Aug;22(8):1259-68 19176219 - Antiviral Res. 2009 May;82(2):A99-109 Letendre, SL (B12) 2004; 56 Masliah, E, Heaton, RK, Marcotte (B15) 1997; 42 Wiley, C, Schrier, R, Nelson, J, Lampert, PW, Oldstone, MB (B23) 1986; 83 Ellis, RJ (B5) 2000; 54 Kis, O, Robillard, K, Chan, GNY, Bendayan, R (B9) 2010; 31 Heaton, RK (B8) 2011; 17 Saumoy, M (B19) 2011; 12 Letendre, SL, Capparelli, EV, Ellis, RJ, McCutchan, JA (B11) 2000; 44 Cysique, LA (B4) 2009; 73 Tozzi, V (B21) 2009; 52 Letendre, S (B10) 2008; 65 Parkin, NT (B17) 2004; 48 Capparelli, EV (B3) 2005; 19 Best, BM (B2) 2009; 23 Ellis, RJ (B7) 2002; 59 Ellis, RJ (B6) 1997; 42 Sadler, B (B18) 2001; 45 Sevigny, JJ (B20) 2004; 63 Letendre, SL (B13) 2007; 54 McArthur, JC (B16) 1997; 42 Bachmeier, CJ, Spitzenberger, TJ, Elmquist, WF, Miller, DW (B1) 2005; 22 Marra, CM (B14) 2009; 23 Varatharajan, L, Thomas, SA (B22) 2009; 82 |
| References_xml | – volume: 59 start-page: 923 year: 2002 ident: e_1_3_2_8_2 article-title: Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA publication-title: Arch. Neurol doi: 10.1001/archneur.59.6.923 – volume: 54 start-page: 1511 year: 2007 ident: e_1_3_2_14_2 article-title: Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid publication-title: Clin. Infect. Dis doi: 10.1086/523002 – volume: 52 start-page: 56 year: 2009 ident: e_1_3_2_22_2 article-title: Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders publication-title: J. Acquir. Immune Defic. Syndr doi: 10.1097/QAI.0b013e3181af83d6 – ident: e_1_3_2_3_2 doi: 10.1097/QAD.0b013e328317a702 – ident: e_1_3_2_18_2 doi: 10.1128/AAC.48.2.437-443.2004 – volume: 63 start-page: 2084 year: 2004 ident: e_1_3_2_21_2 article-title: Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia publication-title: Neurology doi: 10.1212/01.WNL.0000145763.68284.15 – volume: 73 start-page: 342 year: 2009 ident: e_1_3_2_5_2 article-title: Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy publication-title: Neurology doi: 10.1212/WNL.0b013e3181ab2b3b – ident: e_1_3_2_7_2 doi: 10.1002/ana.410420503 – ident: e_1_3_2_12_2 doi: 10.1128/AAC.44.8.2173-2175.2000 – ident: e_1_3_2_17_2 doi: 10.1002/ana.410420504 – volume: 23 start-page: 1359 year: 2009 ident: e_1_3_2_15_2 article-title: Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance publication-title: AIDS doi: 10.1097/QAD.0b013e32832c4152 – volume: 22 start-page: 1259 year: 2005 ident: e_1_3_2_2_2 article-title: Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier publication-title: Pharm. Res doi: 10.1007/s11095-005-5271-y – ident: e_1_3_2_9_2 doi: 10.1007/s13365-010-0006-1 – ident: e_1_3_2_24_2 doi: 10.1073/pnas.83.18.7089 – volume: 56 start-page: 416 year: 2004 ident: e_1_3_2_13_2 article-title: Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders publication-title: Ann. Neurol doi: 10.1002/ana.20198 – ident: e_1_3_2_6_2 doi: 10.1212/WNL.54.4.927 – ident: e_1_3_2_11_2 doi: 10.1001/archneurol.2007.31 – ident: e_1_3_2_4_2 doi: 10.1097/01.aids.0000171409.38490.48 – volume: 82 start-page: A99 year: 2009 ident: e_1_3_2_23_2 article-title: The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research publication-title: Antiviral Res doi: 10.1016/j.antiviral.2008.12.013 – ident: e_1_3_2_10_2 doi: 10.1016/j.tips.2009.10.001 – volume: 12 start-page: 438 year: 2011 ident: e_1_3_2_20_2 article-title: Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study) publication-title: HIV Med doi: 10.1111/j.1468-1293.2010.00898.x – volume: 42 start-page: 963 year: 1997 ident: e_1_3_2_16_2 article-title: Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center publication-title: Ann. Neurol doi: 10.1002/ana.410420618 – ident: e_1_3_2_19_2 doi: 10.1128/AAC.45.12.3663-3668.2001 – reference: 19731418 - J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63 – reference: 9392567 - Ann Neurol. 1997 Nov;42(5):689-98 – reference: 16078135 - Pharm Res. 2005 Aug;22(8):1259-68 – reference: 19474412 - Neurology. 2009 Aug 4;73(5):342-8 – reference: 10690988 - Neurology. 2000 Feb 22;54(4):927-36 – reference: 9403489 - Ann Neurol. 1997 Dec;42(6):963-72 – reference: 15349869 - Ann Neurol. 2004 Sep;56(3):416-23 – reference: 15596754 - Neurology. 2004 Dec 14;63(11):2084-90 – reference: 18195140 - Arch Neurol. 2008 Jan;65(1):65-70 – reference: 12056927 - Arch Neurol. 2002 Jun;59(6):923-8 – reference: 9392566 - Ann Neurol. 1997 Nov;42(5):679-88 – reference: 19424052 - AIDS. 2009 Jul 17;23(11):1359-66 – reference: 14742192 - Antimicrob Agents Chemother. 2004 Feb;48(2):437-43 – reference: 3018755 - Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089-93 – reference: 20004485 - Trends Pharmacol Sci. 2010 Jan;31(1):22-35 – reference: 21729229 - HIV Med. 2011 Aug;12(7):438-41 – reference: 10898694 - Antimicrob Agents Chemother. 2000 Aug;44(8):2173-5 – reference: 11709366 - Antimicrob Agents Chemother. 2001 Dec;45(12):3663-8 – reference: 15905676 - AIDS. 2005 Jun 10;19(9):949-52 – reference: 19176219 - Antiviral Res. 2009 May;82(2):A99-109 – reference: 19050389 - AIDS. 2009 Jan 2;23(1):83-7 – reference: 21174240 - J Neurovirol. 2011 Feb;17(1):3-16 – volume: 45 start-page: 3663 year: 2001 end-page: 3668 ident: B18 article-title: Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir publication-title: Antimicrob. Agents Chemother – volume: 82 start-page: A99 year: 2009 end-page: A109 ident: B22 article-title: The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research publication-title: Antiviral Res – volume: 59 start-page: 923 year: 2002 end-page: 928 ident: B7 article-title: Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA publication-title: Arch. Neurol – volume: 23 start-page: 1359 year: 2009 end-page: 1366 ident: B14 article-title: Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance publication-title: AIDS – volume: 22 start-page: 1259 year: 2005 end-page: 1268 ident: B1 article-title: Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier publication-title: Pharm. Res – volume: 63 start-page: 2084 year: 2004 end-page: 2090 ident: B20 article-title: Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia publication-title: Neurology – volume: 31 start-page: 22 year: 2010 end-page: 35 ident: B9 article-title: The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters publication-title: Trends Pharm. Sci – volume: 42 start-page: 679 year: 1997 end-page: 688 ident: B6 article-title: Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group publication-title: Ann. Neurol – volume: 19 start-page: 949 year: 2005 end-page: 952 ident: B3 article-title: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV publication-title: AIDS – volume: 52 start-page: 56 year: 2009 end-page: 63 ident: B21 article-title: Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders publication-title: J. Acquir. Immune Defic. Syndr – volume: 54 start-page: 1511 year: 2007 end-page: 1517 ident: B13 article-title: Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid publication-title: Clin. Infect. Dis – volume: 17 start-page: 3 year: 2011 end-page: 16 ident: B8 article-title: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors publication-title: J. Neurovirol – volume: 65 start-page: 65 year: 2008 end-page: 70 ident: B10 article-title: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system publication-title: Arch. Neurol – volume: 83 start-page: 7089 year: 1986 end-page: 7093 ident: B23 article-title: Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients publication-title: Proc. Natl. Acad. Sci. U. S. A – volume: 73 start-page: 342 year: 2009 end-page: 348 ident: B4 article-title: Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy publication-title: Neurology – volume: 42 start-page: 689 year: 1997 end-page: 698 ident: B16 article-title: Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain publication-title: Ann. Neurol – volume: 56 start-page: 416 year: 2004 end-page: 423 ident: B12 article-title: Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders publication-title: Ann. Neurol – volume: 48 start-page: 437 year: 2004 end-page: 443 ident: B17 article-title: Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 publication-title: Antimicrob. Agents Chemother – volume: 54 start-page: 927 year: 2000 end-page: 936 ident: B5 article-title: Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources publication-title: Neurology – volume: 42 start-page: 963 year: 1997 end-page: 972 ident: B15 article-title: Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center publication-title: Ann. Neurol – volume: 23 start-page: 83 year: 2009 end-page: 87 ident: B2 article-title: Low atazanavir concentrations in cerebrospinal fluid publication-title: AIDS – volume: 12 start-page: 438 year: 2011 end-page: 441 ident: B19 article-title: Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study) publication-title: HIV Med – volume: 44 start-page: 2173 year: 2000 end-page: 2175 ident: B11 article-title: Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group publication-title: Antimicrob. Agents Chemother |
| SSID | ssj0006590 |
| Score | 2.1246302 |
| Snippet | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better... |
| SourceID | pubmedcentral proquest asm2 pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1985 |
| SubjectTerms | Adult Anti-HIV Agents Anti-HIV Agents - administration & dosage Anti-HIV Agents - cerebrospinal fluid Anti-HIV Agents - pharmacokinetics Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Biological and medical sciences Carbamates Carbamates - administration & dosage Carbamates - cerebrospinal fluid Carbamates - pharmacokinetics CD4-Positive T-Lymphocytes Chromatography, High Pressure Liquid Drug Administration Schedule Drug Therapy, Combination Female HIV Infections - blood HIV Infections - cerebrospinal fluid HIV-1 Humans Inhibitory Concentration 50 Male Medical sciences Middle Aged Pharmacology Pharmacology. Drug treatments Sulfonamides Sulfonamides - administration & dosage Sulfonamides - cerebrospinal fluid Sulfonamides - pharmacokinetics Tandem Mass Spectrometry |
| Title | Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid |
| URI | http://aac.asm.org/content/56/4/1985.abstract https://www.ncbi.nlm.nih.gov/pubmed/22290964 https://journals.asm.org/doi/10.1128/AAC.05098-11 https://www.proquest.com/docview/1009523736 https://pubmed.ncbi.nlm.nih.gov/PMC3318381 |
| Volume | 56 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEIgXBOUrA6aAYC9byuI4H5Z4iSqmCaloQpu0N8txnS1iTVE_kMoDfzt3sfM1ddLgJWoT10pz5zvf5X6_I-SDZrDCfCa9qYoij_maejxBeu0j5dNcwoY5QDTy5Ft0cs6-XoQXg8GfLrpklY3U7624kv-RKpwDuSJK9h8k20wKJ-AzyBeOIGE43lXGNXjqIJ0hO6X8VSwQxWdqLps68bFeQOyLLUJw83l8vS56_TnTclXMioqSCakDLivUWwV4u9IzC9FqUu9jZHaQ6xsF8VjSg-l0m9JGxocm0tcGVwIR__xHodv863dw0IUtNQOba7OwNgWBtRysV85Rv1vqFppOipZIqmuAUSMS03F4pI3NRUrTKDSNbWujbNjGrfKxjoX1uWnxY701lnxt9wQU0Q1pOh4hww1Eyn7r8Zo6xPrSPXKfQphB62yP9eRwUwbCZG-6Bk7Q5FN3YvDmcjmj_Z1NzTaNxbZyCestN41StkUyNwtyOzucsyfksQ1N3NTo2VMy0OWQPDDNSjdD8nBiyzCGZP_UEJ5vDt2OCi4P3X33tKVC3zwjnzuX3VZD3b6GukXp9jTUrTT0OTk__nI2PvFsvw5PspitvCzS00hTlcUQZEvOwwQNRCgp0zKpcKkhGIQkVlLrWPsJp1keqZxlIQ-yMOfBC7JTzkv9iriKg6_JIaTKeAQhxVSyIz6FnW0sc8qVyh3yHh-5sItxKapYliYC5CIqucBXhxzUAhHKMt5j45XrW0Z_bEb_NEwvt4zbrWUr4B6ElEqEkWACNdMhez1pNzNBZMGxmtwh72rxCzDk-HZOlnq-xn8A0Q4N4iByyEujDu2vsSsDPAmHxD1FaQYgSXz_SllcVWTxATrtxN-9ywN7TR61y_sN2Vkt1vot7LlX2V61MP4CJIHWKg |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+Amprenavir+Concentrations+in+Cerebrospinal+Fluid&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Croteau%2C+David&rft.au=Letendre%2C+Scott&rft.au=Best%2C+Brookie+M&rft.au=Rossi%2C+Steven+S&rft.date=2012-04-01&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=56&rft.issue=4&rft.spage=1985&rft.epage=1989&rft_id=info:doi/10.1128%2FAAC.05098-11&rft.externalDocID=05098-11 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |